This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Albany Molecular Research Inc (AMRI)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 12.68M -3.78M 0.00 -62.87M
Operating Gains/Losses 234.00K 176.00K 83.00K 331.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -9.33M -13.57M 2.73M -7.98M
(Increase) Decrease in Inventories -5.14M -2.21M 215.00K -1.34M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 7.70M 196.00K -11.95M 15.51M
(Decrease) Increase In Other Current Liabilities 3.59M 0.00 0.00 -8.74M
(Increase) Decrease In Other Working Capital -2.60M 1.94M -5.34M -1.20M
Other Non-Cash Items 3.98M 10.42M -8.19M 51.21M
Net Cash From Continuing Operations 28.18M 15.34M -1.48M -1.32M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 28.18M 15.34M -1.48M -1.32M
Sale of Property, Plant & Equipment 300.00K 447.00K 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -11.55M -10.44M -11.26M -12.65M
Acquisitions 0.00 0.00 0.00 -46.34M
Purchases of Short-Term Investments 0.00 0.00 -817.00K -7.82M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -11.25M -9.78M 3.97M -45.06M
Issuance of Debt 150.00M 5.00M 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 24.63M 531.00K 671.00K 0.00
Repayment of Long-Term Debt -775.00K -2.84M -7.37M -270.00K
Repurchase of Capital Stock -164.00K 0.00 0.00 -10.00M
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -36.80M -5.23M -270.00K 592.00K
Net Cash From Financing Activities 136.88M -2.53M -6.97M -9.68M
Effect of Exchange Rate Changes -1.18M 288.00K -1.28M 850.00K
Net Change in Cash & Cash Equivalents 152.64M 3.31M -5.76M -55.21M

AMRI Albany Molecular Research Inc

Analysts Ratings for AMRI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 1
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1

Brokerage Partners

AMRI Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs